Hepatic impairment No dose adjustment is needed in people with delicate or reasonable (Boy or girl-Pugh A or B) hepatic impairment (see section five.two). Exposure to midostaurin and its active metabolite CGP62221 is substantially decreased in individuals with critical hepatic impairment than that in people with typical hepatic functionality (see https://clivee186uae9.dailyblogzz.com/profile